**Effects of adherence to pharmacological secondary prevention after acute myocardial infarction on health care costs – an analysis of real-world data**

Florian Kirsch1,2, Christian Becker2, Christoph Kurz2, Lars Schwettmann2, Anja Schramm3

Affiliation:

1 Munich School of Management and Munich Center of Health Sciences, Ludwig-Maximilians-University, Munich, Germany

2 Institute of Health Economics and Health Care Management, HelmholtzZentrum München, Neuherberg, Germany

3 AOK Bayern, Service Center of Health Care Management, Regensburg, Germany

Correspondence: Dr. Florian Kirsch, MBR, Institute of Health Economics and Health Care Management, HelmholtzZentrum München, Ingolstädter Landstraße 1, D-85764 Neuherberg, Germany; phone: +49 (0) 89 / 3187 – 49223; E-mail: florian.kirsch@helmholtz-muenchen.de

**Acknowledgements**

We would like to thank the AOK Bayern for providing the data and the helpful comments on data.

**Conflict of interest statement**

No funding was provided for the preparation of the manuscript.

**Conflict of interest statement**

The authors have no relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes, employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

**Keywords**

Acute myocardial infarction, health care expenditures, secondary prevention, guideline-based medication, Disease Management Program.